期刊文献+

初探酶联免疫斑点法检测T细胞免疫功能质控要点 被引量:2

下载PDF
导出
摘要 恶性肿瘤逐渐成为影响人类健康的主要因素,在传统治疗手段的基础上,人们开始关注免疫功能在疾病发生过程中的变化情况,而肿瘤细胞在人体中的免疫反应主要以细胞免疫为主,如何高效、准确地检测特异性细胞免疫功能的变化成为研究的热点[1]。在诸多的免疫检测方法中,酶联免疫斑点法(ELISPOT)由于其灵敏度高、特异性强、操作简便而受到重视。该方法可以有效检测特异性抗体分泌细胞的数量和功能,可以在单细胞水平测定分泌特定细胞因子的功能和细胞数量,广泛应用于人类免疫缺陷病毒疫苗、病毒感染相关疾病及肿瘤等方面的研究中[2‐5]。目前本实验室应用ELISPOT 技术检测 EB 病毒(EBV)感染的鼻咽癌患者放射治疗前后特异性T 细胞免疫功能的变化情况,筛选特定的多肽,并致力于为生物治疗提供临床依据,已经取得初步的结果[6‐7]。由于ELISPOT 技术的高敏感性,实验的结果容易受到诸多因素的影响,为了得到真实、准确的结果,严格规范实验流程,加强实验室的质量控制是确保实验结果的关键。经过近年来对ELISPOT 技术的应用及总结,现将ELISPOT 技术的质控要点总结如下。
出处 《检验医学与临床》 CAS 2014年第23期3384-3385,共2页 Laboratory Medicine and Clinic
基金 新疆维吾尔自治区国际合作资助项目(20126024 201141138)
  • 相关文献

参考文献11

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statis- tics[J]. CA Cancer J C1in,2011,61(2) :69-90.
  • 2Bae J, Smith R, Daley J, et al. Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a po tential therapeutic application in multiple myeloma and other plasma cell disorders[J]. Clin Cancer Res, 2012,18 (17) :4850-4860.
  • 3Hashem M,E1-Karaksy H, Shata MT, et al. Strong hepa- titis C virus (HCV)-specific cell mediated immune re- sponses in the absence of viremia or antibodies among un- infected siblings of HCV chronically infected children[J]. J Infect Dis,2011,203(6) :854-861.
  • 4Camisasehi C, Casati C, Rini F, et al. LAG-3 expression defines a subset of CD4 ( 4. ) CD25 (high) Foxp3 ( 4- ) regu- latory T cells that are expanded at tumor sites[J]. J Im- munol,2010,184(11) :6545-6551.
  • 5Kawakami Y, Yaguehi T, Sumimoto H, et al. Cancer-in- duced immunosuppressive cascades and their reversal by molecular-targeted therapy[J]. Ann N Y Aead Sci, 2013, 1284:80-86.
  • 6王若峥,谭遥,王多明,黄莉,李晓霞.酶联免疫斑点法检测鼻咽癌患者放疗前后T细胞对EB病毒肽段的特异性反应[J].肿瘤防治研究,2009,36(11):928-931. 被引量:6
  • 7王若峥,谭遥,黄丽,王多明,吾甫尔.ELISPOT法检测鼻咽癌放疗前后细胞免疫反应的变化[J].广西医科大学学报,2009,26(3):420-422. 被引量:1
  • 8Suzuki H,Fukuhara M, Yamaura T, et al. Multiple thera- peutic peptide vaccines consisting of combined novel canc- er testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer[J]. J Transl Med, 2013, 11(1):97.
  • 9Rasmussen SB, Harndahl MN, Stryhn A, et al. Peptide pool immunization and CD8-l- T cell reactivity[J]. Immu nol Lett,2013,151(1/2) :48-53. S.
  • 10ingh SK, Meyering M, Ramwadhdoebe TH, et al. The simultaneous ex vivo detection of low-frequency antigen specific CD4-1- and CD8 + T-cell responses using over- lapping peptide pools[J]. Cancer Immunol Immunother, 2012,61(11) :1953-1963.

二级参考文献24

  • 1刘泰福,徐国镇.全国鼻咽癌会议纪要[J].中华放射肿瘤学杂志,1992,0(4):5-10. 被引量:132
  • 2王耀春,张萍,李巍,韩骅.EBNA2基因真核表达载体的构建及表达产物的功能[J].第四军医大学学报,2006,27(5):428-430. 被引量:3
  • 3温文胜,张哲,谢莹,徐志文,黄光武.鼻咽癌患者外周血中CD4^+CD25^+调节性T细胞的检测[J].广西医科大学学报,2007,24(3):379-381. 被引量:3
  • 4Braun RP,Payne LG,Dong L.Characterization of the IFN-gamma T-cell responses to immediate early antigens in humans with genital herpes[J].Virol J,2006,5(3):54.
  • 5ChakrabortyM,Abrams SI,Coleman CN,et al.External beamradiation of tumor altersphenotype of tumor cells to render them susceptible to vaccinemediated T cell killing[J].Cancer Res,2004,64(12):4 328-4 337.
  • 6Czerkinsk y C,Andersson G,Ekre.HP,et al.Reverse Elispot assay for clonal analysis of cytokine production[J].J Immunol Methods,1988,110(1):29-36.
  • 7Chi KH,Liu SJ,Li CP,et al.Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma[J].J Immunother,2005,28(2):129-135.
  • 8Welters MJ,Piersma SJ,van der Burg.SHT-regulatory cells in tumour-specific vaccination strategies[J].Expert Opin Biol Ther,2008,8(9):1 365-1 379.
  • 9Martorelli D,Houali K,Caggiari L,et al.Spontaneous T cell responses to Epstein-Barr virus-encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma:bases for improved immunotherapy[J].Int J Cancer,2008,123(5):1 100-1 107.
  • 10Eric A Reits,James W Hodge,Carla A,et al.Radiation modulates the peptide repertoire,enhances MHC class I expression,and induces successful antitumor immunotherapy[J].The Journal of Experimental Medicine,2006,203(5):1 259-1 272.

共引文献5

同被引文献22

  • 1OTTENHOFF T H, KAUFMANN S H. Vaccines against tuber- culosis: where are we and where do we need to go [J]. PLoS Pathog, 2012, 8 (5): e1002607.
  • 2PRABHU M,BHANUPRAKASH V,VENKATESAN G,et al.Evaluation of stability of live attenuated camelpox vaccine stabilized with different stabilizers and reconstituted with various diluents[J].Biologicals,2014,42(3):169-175.
  • 3DA FONSECA D M,SILVA C L,PAULA M O,et al.Increased levels of interferon-γprimed by culture filtrate protein antigen and Cp G-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection[J].Immunology,2007,121(4):508-517.
  • 4LI H,NOOKALA S,RE F.Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1βand IL-18 release[J].J Immunol,2007,178(8):5271-5276.
  • 5RIMANIOL A C,GRAS G,VERDIER F,et al.Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type[J].Vaccine,2004,22(23-24):3127-3135.
  • 6LI X R,ALDAYEL A M,CUI Z R.Aluminum hydroxide nanoparticles show a stronger vaccine adjuvant activity than traditional aluminum hydroxide microparticles[J].J Control Release,2014,173(1):148-157.
  • 7XIAO Y H,ZENG Y,ALEXANDER E,et al.Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/Cp G vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge[J].Vaccine,2013,31(2):319-326.
  • 8SIVAKUMAR S M,SAFHI M M,KANNADASAN M,et al.Vaccine adjuvants-current status and prospects on controlled release adjuvancity[J].Saudi Pharm J,2011,19(4):197-206.
  • 9HAFNER A M,CORTHSY B,MERKLE H P.Particulate formulations for the delivery of poly(I:C)as vaccine adjuvant[J].Adv Drug Rev,2013,65(10):1386-1399.
  • 10HANSEN J,LINDENSTROM T,LINDBERG-LEVIN J,et al.CAF05:cationic liposomes that incorporate synthetic cord factor and poly(I:C)induce CTL immunity and reduce tumor burden in mice[J].Cancer Immunol Immunother,2012,61(6):893-903.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部